



# **News Release**

## **MOLTENI APPOINTS NORGINE AS ITS MARKETING PARTNER FOR ORAMORPH® IN EUROPE**

Molteni Farmaceutici and Norgine today announced that Molteni has appointed Norgine as its marketing partner for ORAMORPH® in ten major markets in Europe. The deal covers rights to the full range of ORAMORPH® liquid morphine products, for use in the treatment of severe pain.

Commenting on the deal Peter Stein, Managing Director of Norgine International, said, "We are delighted that Molteni has selected Norgine as their marketing partner for ORAMORPH®. This is Norgine's first entry into the pain management products market and is an excellent fit with our lead product MOVICOL®. We look forward to working closely with our partners at Molteni as we launch ORAMORPH® across Europe".

Dr. Giuseppe Seghi Recli, Managing Director of Molteni Farmaceutici commented "We are pleased to be working with Norgine as our partner for the other major European markets outside Italy. ORAMORPH® is a product with a unique formulation of the active ingredient which provides, according to the latest recommendations of the WHO, the best means of adjusting the dose and consequently guarantees excellent product compliance, one of the key factors in the treatment of severe pain. We are very confident that Norgine is the right partner to market it successfully across Europe".

Norgine is a specialty pharmaceutical company with a strong presence throughout the major markets in Europe. Norgine develops and markets innovative pharmaceutical products addressing serious unmet medical needs with a focus on gastroenterology, hepatology and pain management. Additional information about Norgine can be found at [www.norgine.com](http://www.norgine.com)

Founded in 1892, Molteni Farmaceutici is one of the oldest independent pharmaceutical companies in Italy with its own presence in Italy and Poland. Molteni has a strong know-how in the area of pain and drug addiction management, with its own research program since 1990 targeting resistant bacterial infections through patented molecules in the photodynamic therapy.

More information about Molteni Farmaceutici can be found at [www.moltenifarma.it](http://www.moltenifarma.it)